EDT.TO/ Spectral medical

[beeker]

I'd highlight this statement below from this AM's PR
It's maybe the most positive statement I've seen outa this company in years.
If this passes the FDA it'll be decent money Red...plus the pump is still an extremely attractive as asset.


Chris Seto, CEO of Spectral, commented, “As we head into 2022, the Tigris trial is well positioned to accelerate enrollment and finalize the trial as expeditiously as possible. While it’s important for the overall clinical environment to continue to normalize, we now have the full complement of sites engaged. Furthermore, we are encouraged by the current mortality results, which exceed expectations.”

Intrigued by this play. Throwing some money in...

It's all about diagnostics from here. They have diagnostics and a remedy against some nasty stuff.

 

[Bozzie]

Call is in an hour and a half..I can't see it being material info with the market open..
If some PR comes out in the next hour or so I'd be excited.

 

[Bozzie]

"SOFA score targets blood pressure and degree of vasopressor "

The vasopressor score is the spot the cartridge has had very positive effects...should help with a positive trial outcome.

Turns out the Vasopressor scoring change is more of a major advantage to moving this along than I thought ... Pretty good call so far.

 

[Bozzie]

Cleveland clinic , Stanford, Mt Sinai , Michigan some decent hitters

 

[Bozzie]

Timelines..At 90 participants ( the dotted line) Baxter can exercise the option for exclusivity on PMX.
Baxter will have the data to pass or play.

 

[Bozzie]

I had a very informative call last week about the company.
I think this fall they make a move to a US market.. witch lead to a conversation about the competitors pumps that are publicly traded.
Outset who went public last year and is valued at 2.3 by the market the stock was underwritten at 27 bucks and It opened at 52 on the first day of trading was the main subject.
I didn't know lot about Outset except it was valley money( Venture capital guys) who saw the opening in the pump market and jumped in and got Outset approved quickly..Very quickly witch I could never understood till this weekend. Apparently the Outset pump is a rehash of another older pump with an added water purifying system and a few other features that were needed to legally make it a new product. This guy I spoke to said he doubts any major will buy them and even questions weather the company will make it at all in the end...I noticed on the 9th Outset added a secondary offering.

Here's the part that's telling..Davita who has +2500 location serving dialysis sessions for those in need did the Human Fault Testing on the Outset pump...Side note DaVita buys their in clinic machines from their biggest competitor Fersenius who owns the nextstage pump. DaVita ran the HF test for outset successfully then got and option to run the Outset machines in clinic at a deep discount instead of buying pump from Fersenius...they passed and will continue to buy their major competitors pump. Says a lot about the Outset machine.

Sounds like DaVita will be running the spectral HF tests coming upon here .. DaVita needs a pump but for now it'll continue supporting it biggest competitor fersenius and the Nextstage platform

Pretty juicy. The Uplist may be a good time to sell my original investment..then let the rest ride .
As far as Outset goes I don't see why it wouldn't be a good short at 54 dollars, new equity offering at 53.50 ..worth watching just for fun.

https://finance.yahoo.com/quote/OM?p=OM&.tsrc=fin-srch

Outset Pump 70,000 = 20,000 building a room with 240 and an expensive water system.. the machine pays for itself in 7.2 years
Spectral's machine (Demi) 20,000 no special hook up..plug and play 1.5 years to pay off


Insurance companies will love Demi.

Without saying them by name its 100% clear DeVita will be the Demi trial partner.

Very very very good news

 

[beeker]

Without saying them by name its 100% clear DeVita will be the Demi trial partner.

Very very very good news

That was my impression as well. Chris referenced staffing shortages that was pointed to in public releases by DaVita. It's the only player that makes sense. Fresenius has their own machine. Baxter likely wants into the HD market, but not Clinics (the newspapers/video stores of the future)

 

[Bozzie]

That was my impression as well. Chris referenced staffing shortages that was pointed to in public releases by DaVita. It's the only player that makes sense. Fresenius has their own machine. Baxter likely wants into the HD market, but not Clinics (the newspapers/video stores of the future)

Baxter is a player for the Demi device and the PMX... no doubt.
Great call, it's available for replay at the site who hosted it.

 

[beeker]

Baxter is a player for the Demi device and the PMX... no doubt.
Great call, it's available for replay at the site who hosted it.

Adapting the Baxter CRRT (or proving its worth) to do HP is also a good call. Baxter machines are ubiquitous. Likely more of a "prepping for eventual commercialization move", but also telling regarding Baxter's thought process. Summer 2022 (= 90 enrollees) will be a vary interesting catalyst.

 

[Bozzie]

Adapting the Baxter CRRT (or proving its worth) to do HP is also a good call. Baxter machines are ubiquitous. Likely more of a "prepping for eventual commercialization move", but also telling regarding Baxter's thought process. Summer 2022 (= 90 enrollees) will be a vary interesting catalyst.

You think it'll be a catalyst although the initial Baxter investment sent the stock down..Go figure? IMO the first 5 million dollar payment didn't wow investors.
You have a very high understanding of the situation ..

thank you for posting.

 

[beeker]

You think it'll be a catalyst although the initial Baxter investment sent the stock down..Go figure? IMO the first 5 million dollar payment didn't wow investors.
You have a very high understanding of the situation ..

thank you for posting.

Personally, I don't think anything announced, up until now at least, has been intended to wow investors. The $ 5M from Baxter never hit the top line. Nasdaq is on the back burner. It is incubating quietly up in Canada - but make no mistake this will be a US story. I suspect they will let the SP run in 2022 with more of a marketing effort....aided by the news of an actual start of the DIMI Trial and a run rate of 15 enrollees/month into Tigris. Both should happen by spring barring something calamitous re: Omicron. Trading way under where it should for its potential IMO. I liken it to an undervalued prime ocean-front Real Estate listing being held back in order to create a bidding war, when they are good and ready.

 

[Bozzie]

you got this....Please update occasionally.
You came at just the right moment.

I'm done here.

 

[beeker]

Takes nerves of steel to buck the trend....but acquiring here. Look for the pace of enrollment to pick up, followed by news on DeVita maybe? It'll be interesting to see if the theory of tax loss selling was correct, and if so, whether the buybacks (after the 30 day wait period) exert some reverse/upward pressure on share price. As Buffet says, buy when there is blood in the streets. If there were underlying problems, insiders would be selling...and they are not !

 

[beeker]

Fresenius had some hurdles to clear in order to buy NxStage a few years back (for $ 1.9B). I'm wondering if DaVita might be prevented from making a similar acquisition of an FDA approved machine? Perhaps Baxter wants to/will play a role, not only as a distributor, but also as an owner?

 

[Bozzie]

Fresenius had some hurdles to clear in order to buy NxStage a few years back (for $ 1.9B). I'm wondering if DaVita might be prevented from making a similar acquisition of an FDA approved machine? Perhaps Baxter wants to/will play a role, not only as a distributor, but also as an owner?

FTC should have killed the deal, Fresenius almost controls the market..I'd think the feds would welcome a new player in the field.
Something looks to be cooking given the volume

 

[beeker]

FTC should have killed the deal, Fresenius almost controls the market..I'd think the feds would welcome a new player in the field.
Something looks to be cooking given the volume

Interesting. You're saying the FTC might allow it, in order to level the playing field between the two biggest players? Another possibility is that a third player is allowed in, who works in concert with one of the two giants of Dialysis .

 

[beeker]

While the small Cdn. incubator is not exactly trumpeting their story here, there is simply too much to offer on Sepsis and Dialysis. As the PMX Trial is in its final phase (phase 3b) with favorable parameters from the FDA, and the final Home Dialysis Study involving 30 some odd participants begins in spring 2022, the good news story will start to leak out in 2022 post Omicron delays. Should be nice gains throughout 2022, and all heck will break loose in 2023 (if there is not a large and "surprise" takeout of one or both pieces before then). All IMHO.

 

[Bozzie]

What Up fellas..?
Someone's building a 20,000 $F building.

DIMI​

Regain control

A new building for 2022​

It was necessary to extend our storage and production capacity, for that, a new building construction has started, end of 2021, and will be in place current 2022. 2000 sqm are planned to even better serve our partners and answer to the patient needs.

 

[Bozzie]

Link

Infomed - Blood purification devices

Infomed is leader in extracorporeal treatment as plasmatherapies and kidney failure. Infomed is specialized in blood purification device.

www.infomed.biz

 

[Knightrofins]

Link

Infomed - Blood purification devices

Infomed is leader in extracorporeal treatment as plasmatherapies and kidney failure. Infomed is specialized in blood purification device.

www.infomed.biz

Hey Stranger!!